AU2017253228B2 - Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease - Google Patents

Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease Download PDF

Info

Publication number
AU2017253228B2
AU2017253228B2 AU2017253228A AU2017253228A AU2017253228B2 AU 2017253228 B2 AU2017253228 B2 AU 2017253228B2 AU 2017253228 A AU2017253228 A AU 2017253228A AU 2017253228 A AU2017253228 A AU 2017253228A AU 2017253228 B2 AU2017253228 B2 AU 2017253228B2
Authority
AU
Australia
Prior art keywords
compound
nash
nafld
formula
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017253228A
Other languages
English (en)
Other versions
AU2017253228A8 (en
AU2017253228A1 (en
Inventor
Peter J. S. Chiu
May Mei-Chi Hsu
Edwin S. C. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of AU2017253228A1 publication Critical patent/AU2017253228A1/en
Publication of AU2017253228A8 publication Critical patent/AU2017253228A8/en
Application granted granted Critical
Publication of AU2017253228B2 publication Critical patent/AU2017253228B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017253228A 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease Active AU2017253228B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (3)

Publication Number Publication Date
AU2017253228A1 AU2017253228A1 (en) 2018-09-27
AU2017253228A8 AU2017253228A8 (en) 2019-01-17
AU2017253228B2 true AU2017253228B2 (en) 2020-04-09

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017253228A Active AU2017253228B2 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Country Status (10)

Country Link
US (1) US10045977B2 (https=)
EP (1) EP3445363A1 (https=)
JP (1) JP2019514872A (https=)
KR (1) KR20180129909A (https=)
CN (2) CN117137917A (https=)
AU (1) AU2017253228B2 (https=)
BR (1) BR112018071705A2 (https=)
CA (1) CA3021788C (https=)
RU (1) RU2717677C1 (https=)
WO (1) WO2017184819A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
ES2929758T3 (es) 2016-05-05 2022-12-01 Childrens Hospital Med Ct Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
CN109475626A (zh) * 2016-07-14 2019-03-15 儿童医院医疗中心 治疗纤维化的方法
KR102729404B1 (ko) 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
EP3694603B1 (en) 2017-10-10 2026-04-08 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
WO2020243633A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CA3236690A1 (en) 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same
EP4413977A4 (en) 2021-11-18 2025-11-05 Inventage Lab Inc METHOD FOR PREPARING MICROPARTICLES CONTAINING LOWLY SOLUBLE MEDICINES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US7923454B2 (en) 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2987788A1 (en) 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
IN2013MU01468A (https=) * 2013-04-22 2015-04-17 Cadila Healthcare Ltd
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN102048733A (zh) * 2010-12-23 2011-05-11 武汉同源药业有限公司 盐酸纳美芬的医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. MOSLEHI ET AL, "Naltrexone attenuates endoplasmic reticulum stress induced hepatic injury in mice", ACTA PHYSIOLOGICA HUNGARICA, HU, (2014-09-01), vol. 101, no. 3, doi:10.1556/APhysiol.101.2014.3.9, ISSN 0231-424X, pages 341 - 352 *
GIOVANNI ADDOLORATO ET AL, "Management of Alcohol Dependence in Patients with Liver Disease", CNS DRUGS, AUCKLAND, NZ, (2013-03-01), vol. 27, no. 4, doi:10.1007/s40263-013-0043-4, ISSN 1172-7047, pages 287 - 299 *

Also Published As

Publication number Publication date
CN109069503A (zh) 2018-12-21
AU2017253228A8 (en) 2019-01-17
CN117137917A (zh) 2023-12-01
US20170304294A1 (en) 2017-10-26
WO2017184819A1 (en) 2017-10-26
RU2717677C1 (ru) 2020-03-25
JP2019514872A (ja) 2019-06-06
KR20180129909A (ko) 2018-12-05
CA3021788C (en) 2021-08-03
BR112018071705A2 (pt) 2019-02-19
AU2017253228A1 (en) 2018-09-27
CA3021788A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
US10045977B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
AU2017253228B2 (en) Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
JP2019514872A5 (https=)
AU2011230081A1 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2016195355A1 (ko) 필버톤의 신규한 용도
JP6377713B2 (ja) 薬剤
JP7184805B2 (ja) 肥満症の予防のためのベタイン
JP2015501849A5 (https=)
JP7759109B2 (ja) Ｅｏｍｅｓ陽性ＣＤ４陽性Ｔ細胞の増加に起因する進行型疾患治療剤
CN120775005A (zh) 一种多肽组合物及其在用于治疗男性勃起功能障碍中的用途
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
TWI710372B (zh) 用於胃輕癱之5-ht4受體激動劑
CN113813281A (zh) 肌苷在制备预防和治疗结核病药物中的应用
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
JP2019041675A (ja) Ｎａｓｈ肝発がんモデル非ヒト動物及びその使用
KR100294329B1 (ko) 간질환 치료 및 예방용 의약 조성물
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN101224212A (zh) 阿魏酸及其钠盐用于制备预防和治疗抑郁症的药物
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
US20140275138A1 (en) Method and products for treating diabetes
JP7720104B2 (ja) トルセミドおよびクロモリンを含む代謝疾患予防または治療用組成物
US20240058300A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用
KR20210020788A (ko) 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
KR20260033973A (ko) 오에노테인 b를 포함하는 대사이상 간 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 37 , PAGE(S) 5229 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME TAIWANJ PHARMACEUTICALS CO., LTD., APPLICATION NO. 2017253228, UNDER INID (72) ADD CO-INVENTOR WU, EDWIN S. C.

FGA Letters patent sealed or granted (standard patent)